Publications

Palmer S, Lin Y, Martin TG, Jagannath S, Jakubowiak A, Usmani SZ, Buyukkaramikli N, Phelps H, Slowik R, Pan F, Valluri S, Pacaud L, Jackson G. Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma. Oncology and therapy. 2023. PMID: 37270762

Ko AH, Kim KP, Siveke JT, Lopez CD, Lacy J, O'Reilly EM, Macarulla T, Manji GA, Lee J, Ajani J, Alsina Maqueda M, Rha SY, Lau J, Al-Sakaff N, Allen S, Lu D, Shemesh CS, Gan X, Cha E, Oh DY. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. Volume 28 of Issue 6 The oncologist. 2023. PMID: 36940261

Garrido-Castro AC, Regan MM, Niman SM, Nakhlis F, Remolano C, Rosenbluth JM, Block C, Warren LE, Bellon JR, Yeh E, Harrison BT, Troll E, Lin NU, Tolaney SM, Overmoyer B, Lynce F. Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer. NPJ breast cancer. 2023. PMID: 37268625

Moey MYY, Hennessy C, French B, Warner JL, Tucker MD, Hausrath DJ, Shah DP, DeCara JM, Bakouny Z, Labaki C, Choueiri TK, Dent S, Akhter N, Ismail-Khan R, Tachiki L, Slosky D, Polonsky TS, Awosika JA, Crago A, Wise-Draper T, Balanchivadze N, Hwang C, Fecher LA, Gomez CG, Hayes-Lattin B, Glover MJ, Shah SA, Gopalakrishnan D, Griffiths EA, Kwon DH, Koshkin VS, Mahmood S, Bashir B, Nonato T, Razavi P, McKay RR, Nagaraj G, Oligino E, Puc M, Tregubenko P, Wulff-Burchfield EM, Xie Z, Halfdanarson TR, Farmakiotis D, Klein EJ, Robilotti EV, Riely GJ, Durand JB, Hayek SS, Kondapalli L, Berg S, O'Connor TE, Bilen MA, Castellano C, Accordino MK, Sibel B, Weissmann LB, Jani C, Flora DB, Rudski L, Dutra MS, Nathaniel B, Ruíz-García E, Vilar-Compte D, Gupta S, Morgans A, Nohria A, COVID-19 and Cancer Consortium. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease. Translational oncology. 2023. PMID: 37302348

Cheng ML, Huang Y, Luong N, LoPiccolo J, Nishino M, Sholl LM, Chirieac LR, Santucci AD, Rabin MS, Jänne PA, Coker S, Diamond JR, Hilton J, Shapiro GI, French CA. Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation. JCO precision oncology. 2023. PMID: 37384867

Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS, CAPItello-291 Study Group. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. The New England journal of medicine. 2023. PMID: 37256976

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Schneider B, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Young JS, Yeung K, Dwyer MA, Kumar R. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. Journal of the National Comprehensive Cancer Network : JNCCN. 2023. PMID: 37308117

Saya Jacob, Zoe Quandt, Michelle E. Melisko, Melanie Majure, Amy Jo Chien, Anne Hudson Blaes, Diane Heditsian, Laura Esserman, Hope S. Rugo. Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors. Journal of Clinical Oncology. 2023. PMID:

Laura Ann Huppert, Elene Tsopurashvili, Sai Sahitha Somepalle, Amy Jo Chien, Melanie Majure, Hope S. Rugo, Ronald Balassanian, Michelle E. Melisko. Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: A single center retrospective cohort study. Journal of Clinical Oncology. 2023. PMID:

Laura Ann Huppert, Amelia S Gliwa, Madeline Tait, Laura Quintal, Stephanie Starzinski, Alexander Cheung, Mark M. Moasser, Melanie Majure, Michelle E. Melisko, Hope S. Rugo, Pamela N. Munster, Michael J. Campbell, Lawrence Fong, Amy Jo Chien. Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC). Journal of Clinical Oncology. 2023. PMID:

Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Hecht JR, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Williams G, Algieri F, Gurski L, Stehman K. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2023. PMID: 37308125

Howard Jinsoo Lee, Louise Christie Walter, Alexander K. Smith, Ying Shi, W. John Boscardin, Harvey Jay Cohen, Grant Richard Williams, Sandra Zeng, Carolyn J Presley, Allison Magnuson, Supriya Gupta Mohile, Surbhi Singhal, Carling Jade Ursem, Ana I. Velazquez Manana, Matthew A. Gubens, Collin M. Blakely, Claire Mulvey, Greg M. Allen, Jonathan Ostrem, Melisa L. Wong. Associations of frailty with overall survival (OS) and functional decline among older adults with non–small-cell lung cancer (NSCLC) receiving chemotherapy, immunotherapy, and/or targeted therapy. Journal of Clinical Oncology. 2023. PMID:

Catherine Choy Smith, Pankit Vachhani, Guillermo Garcia-Manero, Nicole Renee Grieselhuber, Guru Subramanian Guru Murthy, Astha Bhatia, Jatinder Arora, Hooman Izadi, Anthony Fiorino, Raajit Rampal. A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML). Journal of Clinical Oncology. 2023. PMID:

Tempero M. "The Times They Are A-Changin' ". Journal of the National Comprehensive Cancer Network : JNCCN. 2023. PMID: 37308121

Jacqueline V. Aredo, Anatoly Urisman, Matthew A. Gubens, Claire Mulvey, Greg M. Allen, Julia K. Rotow, Daniel Lucas Kerr, Turja Chakrabarti, Bianca Bacaltos, Megan Gee, Kirk Jones, Dara L. Aisner, Tejas Patil, Erin Lynn Schenk, Trever G. Bivona, Jonathan W. Riess, Melissa Coleman, Johannes Ruediger Kratz, David Jablons, Collin M. Blakely. Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR -mutated non-small cell lung cancer. Journal of Clinical Oncology. 2023. PMID:

Edward Maldonado, Thomas A. Hope, Rahul Raj Aggarwal, Daniel H Kwon, Li Zhang, Kelly Gordon, Barry Tong, Adina Bailey, Vipul Kumar, Ivan de Kouchkovsky, Vadim S Koshkin, Hala Borno, Jonathan Chou, Rohit Bose, Lawrence Fong, Arpita Desai, Terence W. Friedlander, Eric Jay Small. Defining the prevalence of inherited DNA damage repair genetic variants (DDRv) in men with prostate cancer (PCa) detected by PSMA PET. Journal of Clinical Oncology. 2023. PMID:

Wang EY, Borno HT, Washington Iii SL, Friedlander T, Zhang S, Trejo E, Van Blarigan EL, Chan JM, Shariff-Marco S, Beatty AL, Kenfield SA. Engaging Men of Diverse Racial and Ethnic Groups With Advanced Prostate Cancer in the Design of an mHealth Diet and Exercise Intervention: Focus Group Study. JMIR cancer. 2023. PMID: 37261885

Alberto Carretero-González, Daniel Kwon, Nonna Shakhnazaryan, Julian C. Hong, Osama Mohamad, Mary Uan-Sian Feng, Ivan de Kouchkovsky, Hala Borno, Rohit Bose, Jonathan Chou, Arpita Desai, Lawrence Fong, Terence W. Friedlander, Vadim S Koshkin, Felix Y Feng, Rahul Raj Aggarwal, Thomas A. Hope, Eric Jay Small. Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging. Journal of Clinical Oncology. 2023. PMID:

Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. 2023. PMID: 37269841

Douglas MP, Ragavan MV, Chen C, Kumar A, Gray SW, Blakely CM, Phillips KA. Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment. Journal of the National Comprehensive Cancer Network : JNCCN. 2023. PMID: 37308126